Michelle Xiaoyan Zhang net worth and biography

Michelle Zhang Biography and Net Worth

Insider of ImageneBio

Michelle Zhang, Ph.D., joined Ikena (then Kyn Therapeutics) in 2016 as Vice President, Research and Development and was later promoted to Senior Vice President, Translational Research and Early Development. At Ikena, she has guided critical progress of the company’s pipeline programs to clinical studies. Dr. Zhang has over 20 years of oncology drug discovery and development experience in biotech as an entrepreneur in residence at Atlas Venture as well as at Curis, Inc. and BioMed Valley Discoveries, and in pharma at Novartis Institutes for Biomedical Research. Her R&D expertise spans across small molecule, antibody, antibody-drug-conjugate, protein and radiopharmaceutical therapeutic and diagnostic modalities. She has led numerous programs from early discovery, translational research and non-clinical evaluations into clinical development. Dr. Zhang received her Ph.D. in Biochemistry from Harvard University.

How do I contact Michelle Xiaoyan Zhang?: The corporate mailing address for Dr. Zhang and other ImageneBio executives is 645 SUMMER STREET SUITE 101, BOSTON MA, 02210. ImageneBio can also be reached via phone at 857-273-8343 and via email at [email protected]. Learn More on Michelle Xiaoyan Zhang's contact information.
Has Michelle Xiaoyan Zhang been buying or selling shares of ImageneBio?: Michelle Xiaoyan Zhang has not been actively trading shares of ImageneBio during the last ninety days. Most recently, Xiaoyan Michelle Zhang sold 3 shares of the business's stock in a transaction on Monday, January 10th. The shares were sold at an average price of $144.00, for a transaction totalling $432.00. Learn More on Michelle Xiaoyan Zhang's trading history.
Who are ImageneBio's active insiders?: ImageneBio's insider roster includes Jean-Francois Formela (Director), and Michelle Zhang (Insider). Learn More on ImageneBio's active insiders.
Are insiders buying or selling shares of ImageneBio?: During the last year, ImageneBio insiders bought shares 2 times. They purchased a total of 351,167 shares worth more than $10,499,893.30. The most recent insider tranaction occured on July, 25th when Director David P Bonita bought 83,611 shares worth more than $2,499,968.90. Insiders at ImageneBio own 5.9% of the company. Learn More about insider trades at ImageneBio.
Information on this page was last updated on 7/25/2025.

Michelle Xiaoyan Zhang Insider Trading History at ImageneBio

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
1/10/2022	Sell	3	$144.00	$432.00
12/10/2021	Sell	83	$177.12	$14,700.96

Michelle Xiaoyan Zhang Buying and Selling Activity at ImageneBio

ImageneBio Company Overview

ImageneBio, Inc., a clinical-stage biotechnology company, develops therapeutics for immunological and inflammatory diseases. Its lead product includes IMG-007, a non-depleting anti-OX40 mAb that has completed Phase 2a clinical trials for the treatment of atopic dermatitis and alopecia areata. The company was formerly known as Ikena Oncology, Inc. and changed its name to ImageneBio, Inc. in July 2025. ImageneBio, Inc. is headquartered in San Diego, California.

Today's Range

Now: $6.78

$6.59

$7.07

50 Day Range

MA: $7.82

$6.21

$8.79

2 Week Range

Now: $6.78

$6.19

$23.28

Volume

71,806 shs

Average Volume

45,412 shs

Market Capitalization

$75.80 million

P/E Ratio

N/A

Dividend Yield